Biotechnology Spatial Genomics Law In Russia.
1. Introduction
Spatial genomics is an emerging branch of biotechnology that examines the location, distribution, and interaction of genes, RNA molecules, proteins, and other biological markers within individual cells, tissues, and organs.
Unlike conventional genomic sequencing, which primarily identifies genetic information, spatial genomics investigates where genetic activity occurs within biological structures and how different cells interact with their surrounding environments.
Its applications include:
Cancer diagnosis and tumour-microenvironment analysis.
Precision medicine and personalised treatment.
Stem-cell and regenerative medicine.
Neuroscience and brain mapping.
Embryonic and developmental biology.
Infectious-disease research.
Organ transplantation and tissue engineering.
Pharmaceutical research and drug discovery.
Russia does not have a single comprehensive federal statute specifically entitled the Spatial Genomics Law. Instead, spatial-genomics activities fall under several existing legal frameworks governing genetic information, biomedical research, personal data, medical devices, biotechnology, intellectual property, and biological safety.
The legal framework must therefore be understood as an interaction between Russian domestic legislation, applicable Eurasian Economic Union regulations, and relevant international obligations.
2. Constitutional framework governing spatial genomics
The Russian Constitution provides the foundational legal principles for spatial-genomics research.
Article 21 – Human dignity
Human dignity must be respected and protected. Research involving human tissues, cells, and biological samples must respect the dignity of research participants.
Article 23 – Privacy and personal secrets
This provision protects private life, personal and family secrets, and confidentiality of communications. It is relevant when spatial-genomics datasets reveal sensitive biological characteristics.
Article 24 – Collection and use of personal information
Public authorities and other organisations cannot arbitrarily collect, store, use, or disseminate information concerning an individual's private life.
Article 41 – Right to health protection
This provision supports the development of healthcare, medical science, and scientific research while requiring protection of public health.
Article 46 – Judicial protection
Individuals and organisations must have access to judicial protection when their constitutional rights are violated through unlawful research practices, misuse of biological samples, or disclosure of confidential genomic information.
3. Federal Law No. 86-FZ of 1996: Genetic engineering regulation
The Federal Law of 5 July 1996 No. 86-FZ, On State Regulation in the Field of Genetic Engineering Activities, is an important component of Russian biotechnology regulation.
It regulates genetic-engineering activities, environmental protection, ecological safety, and human health protection.
Its relevance to spatial genomics requires an important distinction: the law does not create a comprehensive licensing regime for every human-cell sequencing or spatial-transcriptomics experiment.
Article 1 – Scope of application
The law establishes the legal framework for activities involving genetic engineering and related environmental and health-protection issues.
It also excludes certain methods of genetic engineering applied to humans, their tissues, and cells as components of the human organism from its regulatory scope.
Article 2 – Genetic information and genetic data
The legislation distinguishes between:
Genetic information: nucleotide sequences in nucleic-acid polymers.
Genetic data: information presented in a form suitable for collection, systematisation, storage, updating, use, distribution, transfer, and destruction.
This distinction is particularly relevant to spatial genomics because researchers may generate nucleotide-sequence data together with information identifying the precise location of gene expression within tissue.
Practical application
A Russian research institution conducting spatial transcriptomics must determine whether its research involves human genetic data, genetically engineered organisms, or other regulated biological activities.
The mere use of sequencing technology does not automatically make every experiment a genetically engineered activity.
CIS Legislation+1
4. Federal Law No. 242-FZ of 2008: State genomic registration
The Federal Law of 3 December 2008 No. 242-FZ, On State Genomic Registration in the Russian Federation, establishes rules for the collection, storage, processing, use, transfer, and destruction of biological material and genomic information in the state genomic-registration system.
Its principal purpose is the identification of individuals.
Important provisions include:
| Provision | Legal significance |
|---|---|
| Article 1 | Defines biological material, genomic information, and genomic registration |
| Article 2 | Establishes the purposes of state genomic registration |
| Article 7 | Identifies categories subject to compulsory genomic registration |
| Article 9 | Addresses the authorities responsible for genomic registration |
| Article 10 | Establishes security requirements |
| Article 14 | Governs the purposes for which genomic information may be used |
| Article 15 | Identifies authorities entitled to use genomic information |
Article 10 – Security and confidentiality
The collection, storage, processing, and transfer of biological material and genomic information must be organised to prevent loss, damage, distortion, unauthorised access, and unauthorised transfer.
CIS Legislation+1
Application to spatial genomics
Suppose a research organisation collects tumour tissue from patients and generates spatial genomic maps.
The organisation must distinguish between:
Genomic information collected for medical research.
Genomic information collected for state identification purposes.
Biological material stored for scientific investigation.
Medical records associated with genomic profiles.
Federal Law No. 242-FZ should not be treated as a general statutory authorisation for all research laboratories to create or access genomic databases.
5. Federal Law No. 152-FZ of 2006: Personal data protection
The Federal Law of 27 July 2006 No. 152-FZ, On Personal Data, is central to spatial-genomics governance.
Spatial-genomics datasets may contain:
DNA sequences.
RNA expression profiles.
Molecular signatures.
Tissue-specific genetic characteristics.
Disease-associated genomic markers.
Patient identification information.
Information linking biological samples to medical histories.
When these datasets relate to an identifiable individual, personal-data legislation becomes particularly important.
Article 5 – Principles of personal-data processing
Personal data processing must have legitimate and specific purposes. The amount and nature of the information collected should be appropriate to those purposes.
Article 6 – Conditions for processing
Personal data processing must have an appropriate legal basis, such as consent or another statutory ground.
Article 9 – Consent
Where consent is the legal basis, it must satisfy the applicable statutory requirements.
Article 10 – Special categories of personal data
Information concerning health and other specially protected personal characteristics receives additional protection.
Article 18 – Obligations of operators
Organisations processing personal data must comply with applicable requirements concerning data security and, where applicable, localisation of personal-data databases.
Practical example
A Russian hospital collects tissue samples from 500 cancer patients and generates spatial gene-expression maps.
If the maps can be connected to identifiable patients, the hospital must consider:
The lawful basis for processing.
The scope of patient consent.
Confidentiality and access controls.
Data retention.
Security against unauthorised disclosure.
The legal requirements for international data transfers.
Anonymisation may reduce personal-data risks, but merely replacing patient names with codes does not necessarily make a dataset anonymous.
6. Federal Law No. 323-FZ of 2011: Healthcare and biomedical research
The Federal Law of 21 November 2011 No. 323-FZ, On the Fundamentals of Health Protection of Citizens in the Russian Federation, is particularly relevant when spatial genomics is performed in hospitals, clinical laboratories, and medical research institutions.
Important provisions include:
Article 13 – Medical confidentiality
Information concerning a patient's medical condition and treatment is protected by medical-confidentiality requirements.
Spatial-genomics results connected with a patient's medical condition may fall within this protection.
Article 19 – Patient rights
Patients have rights concerning healthcare, medical information, and participation in decisions affecting their treatment.
Article 20 – Informed voluntary consent
Medical interventions generally require informed voluntary consent, subject to statutory exceptions.
Article 22 – Information about health
Patients have rights to receive information about their health, including relevant examination results.
Legal distinction
Consent to undergo a biopsy is not automatically equivalent to consent to unlimited future genomic research, commercial use of samples, or international sharing of identifiable genetic information.
Researchers should establish an appropriate legal basis for each distinct activity.
7. Federal Law No. 180-FZ of 2016: Biomedical cellular products
The Federal Law of 23 June 2016 No. 180-FZ, On Biomedical Cellular Products, is relevant where spatial-genomics research supports the development of cellular therapies or regenerative medical products.
Article 1 – Scope
The legislation regulates the development, preclinical research, clinical trials, examination, registration, manufacture, quality control, storage, transportation, and application of biomedical cellular products.
An important limitation is that Article 1(2) excludes the handling of human cells and tissues for scientific and educational purposes from the law's scope. Therefore, ordinary spatial-genomics research involving human tissue is not automatically regulated as the production of a biomedical cellular product.
Article 2 – Biological material
The law recognises biological materials including:
Human biological fluids.
Human tissues.
Human cells.
Biopsy materials.
Pathological biological samples.
Article 3 – Fundamental principles
The law establishes principles including voluntary and gratuitous donation, medical confidentiality, restrictions on commercial transactions involving biological material, and biological safety.
Article 4 – Preparation of cellular lines
This provision regulates the preparation of cellular lines used in biomedical cellular products.
Practical significance
If spatial-genomics research identifies a particular cell population for developing a regenerative cellular therapy, the legal position changes when the research progresses into the development or manufacture of a regulated biomedical cellular product.
The organisation must then consider the licensing, preclinical, clinical-trial, quality-control, and registration requirements applicable to that product.
CIS Legislation+1
8. The major 2026 development: Federal Law No. 43-FZ
Important legal development – 2026
One of the most significant recent developments for Russian spatial-genomics research is Federal Law No. 43-FZ of 20 February 2026.
This legislation amended Federal Law No. 86-FZ and introduced a specific legal framework for transferring human genetic data.
It is particularly important for spatial-genomics laboratories participating in international research collaborations.
A. Definition of human genetic data
The amendments define human genetic data as information concerning nucleotide sequences in nucleic-acid polymers and their chemical modifications, obtained through molecular-genetic examination of human biological material.
This definition is important because spatial genomics may produce DNA and RNA sequence information alongside spatially resolved molecular data.
B. Population genetic and immunological research
The law defines population genetic and immunological research as research involving more than three people drawn from the general population and grouped according to common characteristics.
These characteristics may include:
Age.
Sex.
Nationality.
Place of residence.
Health condition.
Responses to external influences.
Consequently, a spatial-genomics project involving more than three individuals selected according to common population characteristics may fall within this definition.
C. Article 13.1 – Transfer of human genetic data
The amendments establish a special procedure governing the transfer of human genetic data outside Russia.
The applicable statutory procedure and implementing rules must be considered before sharing covered datasets with foreign recipients.
D. Article 13.2 – Restrictions on population-genetic data
Article 13.2 is especially significant.
It restricts the transfer of genetic data obtained through population genetic or immunological research to specified foreign individuals and organisations, including foreign recipients operating within Russia and recipients outside Russia.
The statutory definition of transfer is broad. It encompasses activities such as:
Collection.
Storage.
Granting access.
Transmission.
Distribution.
Publication or placement on information and telecommunications networks.
Other actions that make the genetic data accessible to the specified recipients.
Exceptional transfers are permitted through the procedure provided under Article 13.1.
Commencement date: Article 13.2 entered into force on 1 September 2026. It is therefore already relevant as of November 2026.
CIS Legislation+1
9. Government Resolution No. 750 of 15 June 2026
The Russian Government adopted Resolution No. 750 of 15 June 2026 concerning the transfer of human genetic data outside the Russian Federation.
This resolution implements the statutory framework introduced through Federal Law No. 43-FZ.
It provides for rules governing the transfer of covered human genetic data and establishes an interdepartmental commission dealing with such transfers.
Application to international spatial-genomics projects
Consider a Russian university collaborating with a German biotechnology company.
The project involves:
Collecting tumour tissue from Russian patients.
Performing spatial transcriptomic sequencing.
Creating gene-expression maps.
Combining genetic information with clinical characteristics.
Uploading the resulting dataset to a foreign research platform.
The university cannot assume that ordinary research consent or a general data-sharing agreement automatically authorises the transfer.
It must first determine whether the project qualifies as population genetic research, whether Article 13.2 applies, and whether the proposed recipient and transfer fall within a statutory exception.
The distinction between access by a foreign research partner and genuinely domestic research processing becomes especially important.
ГАРАНТ+1
10. Intellectual property rights in spatial-genomics research
Russian intellectual property law is primarily governed by Part IV of the Civil Code of the Russian Federation.
Spatial-genomics research may produce several kinds of intellectual property:
| Research output | Potential legal protection |
|---|---|
| Novel sequencing technology | Patent protection |
| New laboratory equipment | Patent protection |
| Innovative tissue-analysis methods | Patent protection, subject to statutory exclusions |
| Spatial-genomics software | Copyright |
| Proprietary analytical databases | Copyright or database-related protection |
| Confidential laboratory protocols | Trade-secret protection |
| New biotechnological inventions | Patent protection, where eligibility requirements are met |
Patentability considerations
The following issues are particularly important:
Novelty of the invention.
Inventive step.
Industrial applicability.
Proper identification of inventors.
Ownership of research-generated inventions.
Employee-created inventions.
University and industry research agreements.
A raw DNA sequence or naturally occurring biological discovery does not automatically become a patentable invention merely because it has been identified through spatial-genomics research.
Similarly, the spatial location of a naturally occurring gene within human tissue does not automatically create an exclusive intellectual-property right.
11. Scientific research ethics and informed consent
Spatial-genomics research raises important ethical issues because biological samples may reveal information beyond the original purpose for which they were collected.
For example, a tumour sample initially collected for cancer diagnosis may reveal:
Previously unknown genetic abnormalities.
Hereditary disease risks.
Familial genetic characteristics.
Molecular indicators of other diseases.
Potential reproductive or developmental information.
Research institutions should therefore establish appropriate ethical and consent procedures.
Important safeguards include:
Clear explanation of the research objectives.
Identification of the biological material being collected.
Disclosure of foreseeable privacy risks.
Explanation of possible future research uses.
Appropriate arrangements for withdrawal of consent where applicable.
Protection of participants' medical information.
Appropriate procedures for communicating clinically significant findings.
The legal distinction between diagnostic use and secondary research use should be maintained throughout the research lifecycle.
12. Important case laws and judicial decisions
There is currently no well-established body of reported Russian judgments specifically addressing spatial transcriptomics, spatial gene-expression mapping, or spatial-genomics databases.
Nevertheless, decisions concerning genomic registration, medical confidentiality, access to genetic evidence, and personal information provide important legal principles.
Case 1. Laptev – Constitutional Court of the Russian Federation, Decision No. 1839-O (3 July 2025)
Direct Russian genomic-law precedent
Court: Constitutional Court of the Russian Federation.
Decision: No. 1839-O.
Date: 3 July 2025.
Background
Oleg Laptev challenged provisions of the State Genomic Registration Law and the Criminal Procedure Code.
His deceased brother's genomic information had been used in criminal investigations through the federal genomic database.
Laptev sought access to information concerning the processing and use of that genomic information.
The authorities refused to provide the requested information.
Legal issues
Who has legal authority to access genomic information?
Can relatives obtain information directly from the federal genomic database?
How should genomic confidentiality be balanced against judicial protection?
What procedural rights exist to challenge genetic evidence?
Decision
The Constitutional Court refused to accept the complaint for consideration.
However, its reasoning clarified several important principles:
Genomic information in the federal database is primarily an official investigative resource.
Access is governed by statutory restrictions.
A person challenging genomic evidence may seek relevant information through criminal-procedure mechanisms.
Authorities cannot arbitrarily reject properly submitted procedural requests.
Judicial protection must remain available where genomic evidence affects legal rights.
Relevance to spatial genomics
This decision is relevant to the legal governance of genomic databases and the confidentiality of genetic information.
For example, a research institution maintaining spatial-genomics profiles must establish appropriate access controls and procedures for responding to legally justified requests.
Important qualification: This case concerns forensic genomic registration, not scientific spatial-genomics research.
ksrf.ru+1
Case 2. Avilkina and Others v. Russia (2013)
Court: European Court of Human Rights.
Application: No. 1585/09.
Judgment: 6 June 2013.
Legal provision: Article 8 of the European Convention on Human Rights.
Background
The case concerned the disclosure of confidential medical records to prosecuting authorities.
The applicants argued that disclosure of their medical information violated their right to respect for private life.
Legal principle
The European Court examined the confidentiality of medical information and the need for adequate justification when authorities seek access to private medical records.
Relevance to spatial genomics
Spatial-genomics information can reveal sensitive medical and biological characteristics.
The principles discussed in this case are relevant when considering:
Disclosure of patient-derived genomic datasets.
Sharing genetic research results with government authorities.
Unauthorised access to biological information.
Confidentiality obligations of research laboratories.
Legal qualification: Russia ceased to be a party to the European Convention on 16 September 2022. This 2013 judgment is therefore a historical human-rights authority, not a basis for treating the Convention as a currently binding treaty obligation on Russia.
HUDOC+1
Case 3. Constitutional Court Decision No. 1-P of 13 January 2020
Court: Constitutional Court of the Russian Federation.
Subject: Access to medical documentation of deceased patients.
This decision is relevant to the relationship between medical confidentiality, relatives' interests, and access to health information.
Legal significance
It provides an important constitutional background for considering whether medical confidentiality should prevent relatives from obtaining information necessary to protect legitimate legal interests.
Application to spatial genomics
Where genomic information is derived from a deceased patient's biological samples, questions may arise concerning:
Access to stored biological samples.
Disclosure of relevant medical records.
Familial genetic information.
The legal interests of surviving relatives.
Confidentiality after death.
This decision should be read alongside the specific statutory provisions governing medical confidentiality and biological material.
ГАРАНТ+1
Case 4. Constitutional Court Decision No. 32-P of 23 November 2017
Court: Constitutional Court of the Russian Federation.
Subject: Access to information protected by legal confidentiality requirements.
The Constitutional Court discussed the balance between information secrecy and the right to obtain information necessary to protect legal interests.
Legal principle
Confidentiality rules should not create unnecessary or insurmountable obstacles to judicial protection.
Application to spatial genomics
This principle is relevant when a researcher, patient, or research participant seeks access to information directly affecting their rights.
For example, a participant challenging the unlawful use of their biological material may require access to relevant research documentation, subject to legitimate confidentiality restrictions.
ГАРАНТ
Summary of relevant judicial authorities
| Case | Main legal principle | Relevance |
|---|---|---|
| Laptev, No. 1839-O (2025) | Genomic database access and confidentiality | Direct genomic-law analogy |
| Avilkina v. Russia (2013) | Medical confidentiality | Genetic privacy |
| Constitutional Court No. 1-P (2020) | Medical records and relatives' interests | Biological sample governance |
| Constitutional Court No. 32-P (2017) | Access to protected information | Research accountability |
These decisions establish relevant legal principles, but they should not be represented as judgments directly deciding the legality of spatial-genomics experiments.
13. Regulatory authorities and institutional responsibilities
Several Russian authorities may have responsibilities depending on the nature of the spatial-genomics activity.
| Authority | Relevant responsibility |
|---|---|
| Ministry of Health | Healthcare policy and medical regulation |
| Roszdravnadzor | Medical supervision and regulatory oversight |
| Roskomnadzor | Personal-data protection and information regulation |
| Rospotrebnadzor | Public-health and sanitary supervision |
| Rospatent | Intellectual-property registration |
| Ministry of Science and Higher Education | Scientific research policy |
| Federal Security Service and other competent authorities | Relevant national-security and legally authorised information-control functions |
The precise competent authority depends on whether the activity involves medical diagnosis, scientific research, regulated products, personal-data processing, or genetic-data transfers.
14. Legal challenges in Russian spatial-genomics regulation
Spatial-genomics research creates several difficult legal questions.
A. Ownership of genomic information
Russian law does not establish a simple universal ownership regime under which every person, laboratory, or hospital automatically owns all genomic information generated from a biological sample.
Questions of control, processing authority, confidentiality, intellectual property, and contractual rights must be considered separately.
B. Secondary use of biological samples
A sample initially collected for diagnostic purposes may later be used for research.
The institution must establish whether the original consent and applicable legal basis cover the proposed secondary use.
C. International research collaboration
The 2026 amendments create particularly important challenges for international spatial-genomics projects.
Sharing covered population-genetic datasets with foreign research institutions may be restricted even where the research is scientifically beneficial.
D. Artificial intelligence and genomic mapping
AI systems may identify patterns in tissue-specific gene expression.
This raises questions concerning:
Algorithmic accuracy.
Reproducibility of research findings.
Scientific accountability.
Patient confidentiality.
Bias in genomic interpretation.
Liability for incorrect medical conclusions.
E. Genetic discrimination
Spatial-genomics findings may disclose information about inherited diseases and biological predispositions.
Appropriate safeguards are necessary to prevent unlawful use of such information in employment, insurance, healthcare, or other decision-making contexts.
F. Research transparency
Institutions must maintain adequate documentation of sample collection, processing, sequencing, analytical methods, and access to research datasets.
15. Hypothetical legal case study
Situation: Russian university and international spatial-genomics collaboration
A Russian university collects tumour samples from 200 patients and creates spatial transcriptomic maps.
A foreign biotechnology company requests access to the complete dataset for cancer-treatment research.
The dataset contains:
RNA sequencing information.
Spatial gene-expression coordinates.
Clinical characteristics.
Patient identification codes.
Tumour-related molecular profiles.
Legal questions
Does Federal Law No. 152-FZ apply?
Does the project qualify as population genetic research under Federal Law No. 43-FZ?
Does Article 13.2 restrict access by the foreign company?
Is an exception under Article 13.1 available?
Does patient consent cover international research collaboration?
Are there additional contractual or intellectual-property restrictions?
Legal analysis
The university must first determine whether the dataset constitutes human genetic data and whether the 200 participants form a population group under the statutory definition.
If the project falls within Article 13.2, the university cannot simply grant the foreign company access because participants consented to research.
It must establish whether the proposed transfer is legally permissible under the applicable exception and implementing procedure.
The university must also satisfy applicable personal-data, medical-confidentiality, research-ethics, and information-security requirements.
Possible legal consequences of non-compliance
Regulatory investigations.
Administrative liability.
Civil claims for damages.
Restrictions on data processing or transfer.
Contractual disputes.
Criminal liability where the elements of a relevant criminal offence are established.
This hypothetical illustrates why international spatial-genomics research requires both scientific and legal oversight.
16. Recommendations for a Russian spatial-genomics compliance framework
Research institutions should establish a structured compliance programme.
Recommended compliance checklist
Research classification: Determine whether the project is clinical research, scientific tissue analysis, population genetics, or regulated biotechnology development.
Sample documentation: Record the source, collection purpose, donor consent, and custody of biological materials.
Data protection: Apply Federal Law No. 152-FZ wherever identifiable personal data are processed.
Genomic-data assessment: Determine whether Federal Law No. 86-FZ and its 2026 amendments apply.
International transfers: Assess Articles 13.1 and 13.2 and Government Resolution No. 750 before granting foreign access.
Clinical regulation: Apply the relevant healthcare and medical-product rules when research is used for diagnosis or treatment.
Ethical oversight: Establish appropriate informed-consent and independent ethical-review procedures.
Security: Implement access restrictions, encryption, audit trails, and appropriate retention and destruction procedures.
Intellectual property: Establish ownership and licensing arrangements for software, inventions, and analytical methods.
Accountability: Maintain records demonstrating compliance with applicable legal obligations.
17. Conclusion
Biotechnology spatial-genomics law in Russia is an emerging regulatory subject rather than a separately codified branch of federal legislation.
Its legal foundation consists primarily of constitutional protections, Federal Law No. 86-FZ, Federal Law No. 242-FZ, Federal Law No. 152-FZ, Federal Law No. 323-FZ, Federal Law No. 180-FZ, and the applicable intellectual-property provisions of the Civil Code.
The most significant recent development is Federal Law No. 43-FZ of 20 February 2026, particularly its provisions governing the transfer of human genetic data obtained through population genetic and immunological research.
Its Article 13.2, effective from 1 September 2026, is particularly important for international genomic research collaborations.
The Constitutional Court's Decision No. 1839-O of 3 July 2025 also provides important guidance on genomic database confidentiality, access to genetic evidence, and procedural protection.
Ultimately, the central legal challenge is to balance scientific innovation, patient autonomy, genetic privacy, national regulatory interests, international research cooperation, and the responsible development of precision medicine in Russia.
18. Important legal references and research sources
Federal Law No. 86-FZ – Genetic Engineering Regulation.
Federal Law No. 242-FZ – State Genomic Registration.
Federal Law No. 43-FZ of 20 February 2026.
Government Resolution No. 750 of 15 June 2026.
Federal Law No. 180-FZ – Biomedical Cellular Products.
Constitutional Court Decision No. 1839-O of 3 July 2025.
Avilkina and Others v. Russia (2013).
Academic note: This is a research-oriented legal overview, not individual legal advice. For practical compliance, the authoritative Russian-language consolidated legislation and the applicable commencement and implementing provisions should be checked.

comments